Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|12|2981-2988

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.12, 2015-12, pp. : 2981-2988

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 10, 2010-09 ,pp. : 504-511

Karger

Access to resources Recommend Favorite

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 329-339

Karger

Access to resources Recommend Favorite

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 328-335

Karger

Access to resources Recommend Favorite

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

By  

CANCER, Vol. 122, Iss. 17, 2016-09 ,pp. : 2646-2653

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic variants in the renin–angiotensin system predict response to bevacizumab in cancer patients

By  

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (ELECTRONIC), Vol. 45, Iss. 12, 2015-12 ,pp. : 1325-1332

John Wiley & Sons Inc

Access to resources Recommend Favorite